Benjamin Davido MD PhD , Blair Merrick MBChB , Prof Ed Kuijper MD PhD , Nicolas Benech MD PhD , Lena M Biehl MD PhD , Silvia Corcione MD PhD , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI)
{"title":"肠道微生物群如何成为对抗多重耐药微生物的目标?","authors":"Benjamin Davido MD PhD , Blair Merrick MBChB , Prof Ed Kuijper MD PhD , Nicolas Benech MD PhD , Lena M Biehl MD PhD , Silvia Corcione MD PhD , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI)","doi":"10.1016/j.lanmic.2024.101063","DOIUrl":null,"url":null,"abstract":"<div><div>The rise of antimicrobial resistance presents a challenge to public health, undermines the efficacy of antibiotics, and compromises the management of infectious diseases. Gut colonisation by multidrug-resistant organisms, such as multidrug-resistant Enterobacterales and vancomycin-resistant enterococci, is associated with increased morbidity and mortality rates, as well as health-care costs. Of late, the role of the gut microbiome in combating colonisation by multidrug-resistant organisms, which could precede invasive infection, has garnered interest. Innovative interventions, including faecal microbiota transplantation, probiotics, phage therapy, and bacterial consortia, represent potential preventive or therapeutic options to counteract colonisation by multidrug-resistant organisms. In this Personal View, we have synthesised the current findings on these interventions and elucidated their potential as solutions to the crisis of antimicrobial resistance.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 8","pages":"Article 101063"},"PeriodicalIF":20.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How can the gut microbiome be targeted to fight multidrug-resistant organisms?\",\"authors\":\"Benjamin Davido MD PhD , Blair Merrick MBChB , Prof Ed Kuijper MD PhD , Nicolas Benech MD PhD , Lena M Biehl MD PhD , Silvia Corcione MD PhD , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI)\",\"doi\":\"10.1016/j.lanmic.2024.101063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The rise of antimicrobial resistance presents a challenge to public health, undermines the efficacy of antibiotics, and compromises the management of infectious diseases. Gut colonisation by multidrug-resistant organisms, such as multidrug-resistant Enterobacterales and vancomycin-resistant enterococci, is associated with increased morbidity and mortality rates, as well as health-care costs. Of late, the role of the gut microbiome in combating colonisation by multidrug-resistant organisms, which could precede invasive infection, has garnered interest. Innovative interventions, including faecal microbiota transplantation, probiotics, phage therapy, and bacterial consortia, represent potential preventive or therapeutic options to counteract colonisation by multidrug-resistant organisms. In this Personal View, we have synthesised the current findings on these interventions and elucidated their potential as solutions to the crisis of antimicrobial resistance.</div></div>\",\"PeriodicalId\":46633,\"journal\":{\"name\":\"Lancet Microbe\",\"volume\":\"6 8\",\"pages\":\"Article 101063\"},\"PeriodicalIF\":20.4000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Microbe\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666524724003318\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666524724003318","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
How can the gut microbiome be targeted to fight multidrug-resistant organisms?
The rise of antimicrobial resistance presents a challenge to public health, undermines the efficacy of antibiotics, and compromises the management of infectious diseases. Gut colonisation by multidrug-resistant organisms, such as multidrug-resistant Enterobacterales and vancomycin-resistant enterococci, is associated with increased morbidity and mortality rates, as well as health-care costs. Of late, the role of the gut microbiome in combating colonisation by multidrug-resistant organisms, which could precede invasive infection, has garnered interest. Innovative interventions, including faecal microbiota transplantation, probiotics, phage therapy, and bacterial consortia, represent potential preventive or therapeutic options to counteract colonisation by multidrug-resistant organisms. In this Personal View, we have synthesised the current findings on these interventions and elucidated their potential as solutions to the crisis of antimicrobial resistance.
期刊介绍:
The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.